Jamie Myers Discusses the Value of Career Development Through ONS Involvement

Jamie Myers, PHD, RN, AOCNS, FAAN, discusses how getting involved in nurse-specific organizations helped advance her professional career.

There are numerous ways to get involved with the Oncology Nursing Society (ONS), Jamie Myers, PHD, RN, AOCNS, FAAN, explained. Furthermore, nurse-specific conferences are a great opportunity to witness what action and leadership look like in the oncology nursing sphere.

Myers, a Research Associate Professor the University of Kansas School of School of Nursing, has conducted various research on the management of symptoms related to cancer and cancer treatment.

Throughout her career, Myers has been recognized as an expert in cancer-related cognitive changes and has been invited to review manuscripts for multiple peer-reviewed journals; served as co-chair of the ONS research grant review team; and served as ad hoc reviewer for grant applications to the Breast Cancer Campaign in the United Kingdom, the National Cancer Institute Biomarker, Imaging, and Quality of Life Studies Funding Program Concept Review, and the American Cancer Society Mentored Scholar Award.

She is chair of the Nursing Research Subcommittee for the SWOG Cancer Research Network and serves on the ONS Putting Evidence Into Practice (PEP) Cognitive Impairment team. In an interview with Oncology Nursing News®, Myers explains how a lot of her accomplishments can be tied to her involvement with ONS.

“Those opportunities that I was able to take advantage of really helped shape my career and career development,” Myers said. “I cannot begin to explain how grateful I am to ONS for that. [Without it], I don't think I would have developed some of the same skill sets that I am using today in my current job.”

Related Videos
Karyn Goodman
Reanne Booker on Factors to Consider When Discussing Palliative Radiation
Grace Choong
Mehra Details the Importance of PD-L1 Expression in HNSCC Treatment Selection
Ahulwalia on Targeting the Blood Brain Barrier With Novel Immunotherapies and Precision Oncology
Related Content
© 2023 MJH Life Sciences

All rights reserved.